Pipeline & Indications
Expanding Therapeutic Horizons for Hard-to-Treat Diseases
We are dedicated to tackling unmet medical needs in antimicrobial resistance and oncology
by developing lipid-based therapeutic
Program
Indication
Pre clinical
IND enabling studies
Phase 01
Nano-Mupirocin
Anti Microbial resistance
Nano-Candesatan
Cancer therapy
LPTL Vaccines
COVID -19
LPTL Vaccines
West Nile virus (WNV)
Pipeline & Indications
Expanding Therapeutic Horizons for Hard-to-Treat Diseases
We are dedicated to tackling unmet medical needs in antimicrobial resistance and oncology
by developing lipid-based therapeutic
Program
Indication
Pre clinical
IND enabling studies
Phase 01
Nano-Mupirocin
Anti Microbial resistance
Nano-Candesatan
Cancer therapy
LPTL Vaccines
COVID -19
LPTL Vaccines
West Nile virus (WNV)
Antimicrobial Resistance:
a Silent Pandemic
Addressing the urgent need for next-gen antimicrobial solutions
Antimicrobial resistance (AMR), a “silent pandemic,” is one of the top global health threats, estimated to be directly responsible for 1.45 million deaths worldwide and projected to cause 40 million deaths by 2050. Antimicrobial resistance (AMR) happens when bacteria evolve and stop responding to treatments. This issue worsens with the overuse or misuse of antibiotics, making infections harder to treat, spreading more easily, and increasing the risk of severe illness or death.
1.45 M
deaths worldwide
40 M
deaths by 2050
The Solution: Revium Rx Nano-Mupirocin
Revium Rx’s nano-mupirocin is a liposomal formulation of the approved, highly effective antibacterial drug mupirocin, which is currently limited to topical use. If approved, the novel proprietary formulation of nano-mupirocin will be administered systemically, providing extended presence in the bloodstream and enhanced delivery of mupirocin to inflamed areas of the body.
Promising Pre-Clinical Results
Preclinical studies by the National Institutes of Health demonstrated that nano-mupirocin has low minimum inhibitory concentration (MIC) levels and effectiveness against antibiotic-resistant strains, including MRSA and VRE.
Solid Tumors
Addressing the limitations of current immunotherapies
Immune checkpoint inhibitors (ICIs) show promise in cancer therapy but are often limited by resistance mechanisms, including the hard-to-penetrate tumor microenvironment (TME). While angiotensin receptor blockers (ARBs) may enhance ICI efficacy by modifying the TME, systemic administration is complicated by their blood pressure–lowering effects.
The Solution: Revium RX Nano Candesartan
Revium Rx’s nano-mupirocin is a liposomal formulation of the approved, highly effective antibacterial drug mupirocin, which is currently limited to topical use. If approved, the novel proprietary formulation of nano-mupirocin will be administered systemically, providing extended presence in the bloodstream and enhanced delivery of mupirocin to inflamed areas of the body.
Results
Preclinical studies carried out at the Hebrew University of Jerusalem have shown that ARB targeting can effectively modulate the immune response within tumors, increasing the effectiveness of currently approved therapies.
Immunization
The critical need for rapid vaccine development in the
case of a pandemic
The COVID-19 pandemic highlighted the critical need for rapid vaccine development, demonstrating that global collaboration can save millions of lives. Yet for many emerging infectious diseases, effective vaccines remain limited, and traditional development faces biological and commercial challenges.
The Solution: Revium’s Lipid-Based Protein-Loaded Technology (LPLT)
Our adaptable LPLT platform uses proprietary lipid assemblies to enhance immune responses in preclinical infectious disease models. By modulating the immune system, LPLT has the potential to improve vaccine efficacy, durability, and safety. Building on lessons from COVID-19, Revium aims to accelerate next-generation vaccines for high-priority threats such as West Nile virus and Zika virus.
Results
Early studies indicate that LPLT could offer a scalable, adaptable strategy to fill critical gaps in vaccine innovation and protect vulnerable populations worldwide.